{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:05:52Z","timestamp":1791378352918,"version":"4.3.2"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12328-026-02421-1","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T13:09:43Z","timestamp":1786108183000},"page":"1320-1327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multidisciplinary treatment with conversion surgery after radiological complete response of liver metastasis to gemcitabine, cisplatin, and durvalumab in metastatic distal cholangiocarcinoma"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7008-1502","authenticated-orcid":false,"given":"Atsushi","family":"Tomioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9313-3923","authenticated-orcid":false,"given":"Nao","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9585-4118","authenticated-orcid":false,"given":"Mitsuaki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1377-7949","authenticated-orcid":false,"given":"Sota","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4710-3803","authenticated-orcid":false,"given":"Yasuhiko","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2294-4673","authenticated-orcid":false,"given":"Hiroki","family":"Hamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1768-9740","authenticated-orcid":false,"given":"Ryo","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6299-3381","authenticated-orcid":false,"given":"Yoshiro","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8274-238X","authenticated-orcid":false,"given":"Mitsuhiro","family":"Asakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-0655","authenticated-orcid":false,"given":"Sang-Woong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"2421_CR1","doi-asserted-by":"publisher","unstructured":"Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","DOI":"10.1056\/EVIDoa2200015"},{"key":"2421_CR2","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","journal-title":"Lancet"},{"key":"2421_CR3","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1097\/JS9.0000000000001540","volume":"110","author":"S Wang","year":"2024","unstructured":"Wang S, Wang Y, Zhu C, et al. Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1\/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study. Int J Surg. 2024;110:4608\u201316. https:\/\/doi.org\/10.1097\/JS9.0000000000001540.","journal-title":"Int J Surg"},{"key":"2421_CR4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.20187","author":"M Abudalou","year":"2021","unstructured":"Abudalou M, Vega EA, Kondratiev S, et al. Complete pathological response to neoadjuvant chemoimmunotherapy in a patient with metastatic intrahepatic cholangiocarcinoma with high tumor mutational burden. Cureus. 2021. https:\/\/doi.org\/10.7759\/cureus.20187.","journal-title":"Cureus"},{"key":"2421_CR5","doi-asserted-by":"publisher","first-page":"e255403","DOI":"10.1136\/bcr-2023-255403","volume":"16","author":"S Zhang","year":"2023","unstructured":"Zhang S, Nie J, Tai S, et al. PD-L1 inhibitor plus gemcitabine and cisplatin therapy followed by conversion surgery for initially unresectable advanced gallbladder cancer. BMJ Case Rep. 2023;16:e255403. https:\/\/doi.org\/10.1136\/bcr-2023-255403.","journal-title":"BMJ Case Rep"},{"key":"2421_CR6","doi-asserted-by":"publisher","first-page":"1173520","DOI":"10.3389\/fimmu.2023.1173520","volume":"14","author":"Q Wang","year":"2023","unstructured":"Wang Q, Mu Y, Ji S, et al. Case report: complete pathological remission of human chorionic gonadotrophin-producing gallbladder carcinoma with multiple liver metastases after treatment with chemotherapy plus an immune checkpoint inhibitor. Front Immunol. 2023;14:1173520. https:\/\/doi.org\/10.3389\/fimmu.2023.1173520.","journal-title":"Front Immunol"},{"key":"2421_CR7","doi-asserted-by":"publisher","first-page":"1353430","DOI":"10.3389\/fimmu.2024.1353430","volume":"15","author":"EKF Leong","year":"2024","unstructured":"Leong EKF, Tan NCH, Pang NQ, et al. Case report: from palliative to potentially curative \u2013 the advent of immunotherapy providing hope to advanced gallbladder adenocarcinoma. Front Immunol. 2024;15:1353430. https:\/\/doi.org\/10.3389\/fimmu.2024.1353430.","journal-title":"Front Immunol"},{"key":"2421_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00572","author":"MD Robinson","year":"2024","unstructured":"Robinson MD, Wheatley R, Foster L, et al. Intrahepatic cholangiocarcinoma with extrahepatic metastasis and high tumor mutation burden: case of complete pathological response to cisplatin\/gemcitabine\/pembrolizumab. JCO Precis Oncol. 2024. https:\/\/doi.org\/10.1200\/PO.23.00572.","journal-title":"JCO Precis Oncol"},{"key":"2421_CR9","doi-asserted-by":"publisher","first-page":"na","DOI":"10.70352\/scrj.cr.25-0023","volume":"11","author":"Y Yasui","year":"2025","unstructured":"Yasui Y, Kimura K, Iseda N, et al. Hilar cholangiocarcinoma with para-aortic lymph node metastasis treated with chemoimmunotherapy and conversion surgery: a case report. Surg Case Rep. 2025;11:na. https:\/\/doi.org\/10.70352\/scrj.cr.25-0023.","journal-title":"Surg Case Rep"},{"key":"2421_CR10","doi-asserted-by":"publisher","first-page":"100219","DOI":"10.1016\/j.iliver.2026.100219","volume":"5","author":"Y Hu","year":"2026","unstructured":"Hu Y, Wei Y, Liu X, et al. Chemotherapy combined with pembrolizumab in advanced gallbladder cancer with subsequent radical resection: a case report. iLIVER. 2026;5:100219. https:\/\/doi.org\/10.1016\/j.iliver.2026.100219.","journal-title":"iLIVER"},{"key":"2421_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1007\/s12328-025-02122-1","volume":"18","author":"K Fukuda","year":"2025","unstructured":"Fukuda K, Kasuga A, Shigematsu Y, et al. Pathological complete response following addition of durvalumab to gemcitabine and cisplatin therapy for intrahepatic cholangiocarcinoma with Lynch syndrome-associated mismatch repair deficiency. Clin J Gastroenterol. 2025;18:520\u20136. https:\/\/doi.org\/10.1007\/s12328-025-02122-1.","journal-title":"Clin J Gastroenterol"},{"key":"2421_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s13691-025-00842-2","volume":"15","author":"T Saijo","year":"2026","unstructured":"Saijo T, Sato H, Aoki S, et al. A case of perihilar cholangiocarcinoma with peritoneal dissemination that achieved a pathological complete response using immune checkpoint inhibitors: a case report. Int Canc Conf J. 2026;15:203\u20139. https:\/\/doi.org\/10.1007\/s13691-025-00842-2.","journal-title":"Int Canc Conf J"},{"key":"2421_CR13","doi-asserted-by":"publisher","first-page":"1724263","DOI":"10.3389\/fimmu.2026.1724263","volume":"17","author":"D Wang","year":"2026","unstructured":"Wang D, Li Y, Shi G, et al. Case Report: Successful conversion of gallbladder cancer with intrahepatic metastases using camrelizumab combined with gemcitabine and cisplatin. Front Immunol. 2026;17:1724263. https:\/\/doi.org\/10.3389\/fimmu.2026.1724263.","journal-title":"Front Immunol"},{"key":"2421_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12328-025-02246-4","volume":"19","author":"M Yamaguchi","year":"2026","unstructured":"Yamaguchi M, Sato S, Kato Y, et al. Durable response to chemotherapy enabling conversion surgery in stage IVB gallbladder cancer: a case successfully treated with durvalumab combined with gemcitabine plus cisplatin. Clin J Gastroenterol. 2026;19:157\u201363. https:\/\/doi.org\/10.1007\/s12328-025-02246-4.","journal-title":"Clin J Gastroenterol"},{"key":"2421_CR15","doi-asserted-by":"publisher","first-page":"1749491","DOI":"10.3389\/fonc.2025.1749491","volume":"15","author":"J Cheng","year":"2026","unstructured":"Cheng J, Li X, Ren C, et al. Multidisciplinary management of surgery and postoperative recurrence in stage IV gallbladder cancer following conversion therapy: a case report. Front Oncol. 2026;15:1749491. https:\/\/doi.org\/10.3389\/fonc.2025.1749491.","journal-title":"Front Oncol"},{"key":"2421_CR16","doi-asserted-by":"publisher","unstructured":"Yoon HH, Orrock JM, Foster NR et al. Prognostic impact of FoxP3\u2009+\u2009Regulatory T Cells in Relation to CD8\u2009+\u2009T Lymphocyte density in human colon carcinomas. Goel A (ed) PLoS ONE. 2012;7:e42274. https:\/\/doi.org\/10.1371\/journal.pone.0042274","DOI":"10.1371\/journal.pone.0042274"},{"key":"2421_CR17","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/eji.202149358","volume":"52","author":"K Itahashi","year":"2022","unstructured":"Itahashi K, Irie T, Nishikawa H. Regulatory T-cell development in the tumor microenvironment. Eur J Immunol. 2022;52:1216\u201327. https:\/\/doi.org\/10.1002\/eji.202149358.","journal-title":"Eur J Immunol"},{"key":"2421_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41419-025-07544-w","volume":"16","author":"Y Pan","year":"2025","unstructured":"Pan Y, Zhou H, Sun Z, et al. Regulatory T cells in solid tumor immunotherapy: effect, mechanism and clinical application. Cell Death Dis. 2025;16:277. https:\/\/doi.org\/10.1038\/s41419-025-07544-w.","journal-title":"Cell Death Dis"},{"key":"2421_CR19","doi-asserted-by":"publisher","first-page":"15179","DOI":"10.1038\/srep15179","volume":"5","author":"B Shang","year":"2015","unstructured":"Shang B, Liu Y, Jiang S, juan, et al. Prognostic value of tumor-infiltrating FoxP3\u2009+\u2009regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5:15179. https:\/\/doi.org\/10.1038\/srep15179.","journal-title":"Sci Rep"},{"key":"2421_CR20","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","volume":"116","author":"T Kamada","year":"2019","unstructured":"Kamada T, Togashi Y, Tay C, et al. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci USA. 2019;116:9999\u201310008. https:\/\/doi.org\/10.1073\/pnas.1822001116.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02421-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-026-02421-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02421-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:43:06Z","timestamp":1791376986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-026-02421-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2421"],"URL":"https:\/\/doi.org\/10.1007\/s12328-026-02421-1","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"13 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors of this manuscript have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to the institutional policy, single-patient case reports are exempt from formal IRB review. Informed consent to participate in this study was obtained from the patient.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of this anonymized case was obtained from the patient.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}